• Natera, Genentech Initiate Phase III Trial Using Signatera americanpharmaceuticalreview
    March 17, 2021
    Natera announced the first patient has been screened in a new phase III clinical trial that uses its tumor-informed, personalized molecular residual disease (MRD) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial ...
PharmaSources Customer Service